Financial Data and Key Metrics Changes - Total revenue for Q2 2024 increased to $2.7 million compared to $0.2 million in the same period last year [20] - Gross profit for the quarter increased to $2.4 million from a loss of $0.3 million in the prior year [20] - Net loss for Q2 2024 was $7.6 million, or a loss of $0.25 per fully diluted share, compared to a net loss of $8.9 million, or a loss of $0.31 per fully diluted share in the prior year [21] - Adjusted EBITDA loss improved to $5.9 million from a loss of $9.6 million in the prior year [21] - Cash position at the end of the quarter was $44.9 million [21] Business Line Data and Key Metrics Changes - Grant revenue in Q2 2024 was $2.5 million, while product revenue was $0.2 million [20] - Research and development expenses decreased to $5.6 million from $6.0 million in the prior year [20] - Total operating expenses decreased to $10.1 million from $11.7 million in the second quarter of 2023 [20] Market Data and Key Metrics Changes - The global total addressable market for tuberculosis (TB) testing is projected to exceed $3.6 billion within the next four years [11] - Approximately 17 million near point-of-care TB tests are performed annually in South and East Asia, with an additional 10 million in Africa [11] Company Strategy and Development Direction - The company is focused on commercializing its Co-Dx PCR platform, with a 510(k) application submitted to the FDA for over-the-counter use [5][6] - Plans to target high-volume care centers and skilled nursing facilities for the initial rollout of the Co-Dx PCR platform [8] - The company aims to expand its test pipeline, including tests for tuberculosis, respiratory multiplex, HPV, and strep [10][12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in the first half of the year and the potential of the Co-Dx PCR platform to transform diagnostics [5][17] - The company is committed to maintaining a healthy balance sheet and operational efficiencies to support long-term growth [21][22] Other Important Information - The company attended two major trade shows, FIME and ADLM, to showcase its Co-Dx PCR platform and engage with potential customers [9] - The vector control business is expanding, with new offerings for mosquito-borne illness surveillance [15] Q&A Session Summary Question: Has there been any feedback from the FDA regarding the 510(k) submission? - Management confirmed regular contact with the FDA but could not comment on specific regulatory decisions [24][25] Question: Are there potential customers showing interest in placing orders once the 510(k) is cleared? - Management indicated constructive conversations with potential customers but emphasized that sales cannot occur until FDA clearance is obtained [26] Question: Is the potential market primarily domestic or international? - Management stated that interest in the product spans both domestic and international markets, with sales in over 50 countries [27]

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 26.47%. A quarter ago, it was expected that this company would post a loss of $0.21 per share when it actually produced a loss of $0.31, delivering a surprise of -47.62%. Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CODX The Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001 ...

Exhibit 99.1 Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results SALT LAKE CITY, August 8, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results: ● Revenue of $2.7 million, up from $0.2 million during the prior year primarily due to the achievement of certain milestones under variou ...

SALT LAKE CITY, July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo held July 28-August 1, 2024, in Chicago, IL. Co-Dx will also be holding a special company presentation to discuss the role of its new at-home and point-ofc ...

SALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will inc ...

SALT LAKE CITY, July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week. About Co-Diagnostics, Inc.: SOURCE Co-Diagnostics Co-Dx vector control technology includes Vector Smart® PCR tests used in environmental ...

The Company will be participating in the Utah booth, displaying the new Co-Dx™ PCR platform*, for which a 510(k) application has been recently submitted to the U.S. Food and Drug Administration for OTC clearance. Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or R ...

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market Co-Diagnostics completed the submission via the FDA's electronic Submissions Template And Resource (eSTAR) system, and have received the acknowledgement from the FDA that the 510(k) application was received. eSTAR serves as a comprehensive resource for medical device manufacturers to standardize and consolidate the necessary in ...

Co-Diagnostics, Inc. (NASDAQ:CODX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference o ...